17-AAG is an ansamycin antibiotic which acts as an anti-tumor agent. Specifically, 17-AAG binds and inhibits Hsp90 (Heat shock protein 90). Hsp90 is a protein chaperone that binds to signaling proteins, known as client proteins. These client proteins include key cancer-relevant targets such as mutated p53, Bcr-Abl, Her2, Akt, Raf-1, B-Raf, and others.17-AAG is able to disrupt the Hsp90-client protein complexes and lead to the degradation of the client proteins.
本公司网站所展示销售的产品仅供科研!
沪公网安备 31011202007337号